Quarterly Securities Report(The second quarter of 145th Business Term) for The Six-month Period and Three-month Quarter Ended September 30, 2021

Table of Contents

Quarterly Securities Report

(The second quarter of 145th Business Term) for The Six-month Period and Three-month Quarter Ended September 30, 2021

TAKEDA PHARMACEUTICAL COMPANY LIMITED

AND ITS SUBSIDIARIES

Table of Contents

Index

		Page
[Cover]	1
A. Company Information
I. Overview of Takeda	2
1.	Key Consolidated Financial Data	2
2.	Business Overview	3
II. Operating and Financial Review	4
1.	Risk Factors	4
2.	Analysis on Business Performance, Financial Position and Cash Flows	4
3.	Material Contracts	22
III. Information on the Company	23
1.	Information on the Company's Shares	23
2.	Members of the Board of Directors	25
IV. Financial Information	26
1.	Condensed Interim Consolidated Financial Statements	27
2.	Others	48
B. Information on Guarantors of the Company	49

Table of Contents
[Cover]
[Document Filed]	Quarterly Securities Report
[Applicable Law]	Article 24-4-7, paragraph 1 of the Financial Instruments and Exchange Act of Japan
[Filed with]	Director, Kanto Local Finance Bureau
[Filing Date]	November 5, 2021
[Fiscal period]	The second quarter of 145th Business Term
	(from July 1, 2021 to September 30, 2021)
[Company Name]	Takeda Pharmaceutical Company Limited
[Title and Name of Representative]	Representative Director, President & Chief Executive Officer
	Christophe Weber
[Address of Head Office]	1-1, Doshomachi 4-chome,Chuo-ku, Osaka
	(Address of the registered head office)
[Telephone Number]	Not applicable
[Name of Contact Person]	Not applicable
[Nearest Place of Contact]	1-1,Nihonbashi-Honcho2-chome,Chuo-ku, Tokyo
	(Global Headquarters)
[Telephone Number]	[phone] (Main telephone number)
[Name of Contact Person]	Norimasa Takeda, Chief Accounting Officer & Corporate Controller, Global Finance
[Place for public inspection]	Takeda Pharmaceutical Company Limited (Global Headquarters)
	(1-1, Nihonbashi Honcho 2-chome,Chuo-ku, Tokyo)
	Tokyo Stock Exchange, Inc.
	(2-1, Nihonbashi Kabutocho, Chuo-ku, Tokyo)
	Nagoya Stock Exchange, Inc.
	(8-20, Sakae 3-chome,Naka-ku, Nagoya)
	Fukuoka Stock Exchange
	(14-2, Tenjin 2-chome,Chuo-ku, Fukuoka)
	Sapporo Stock Exchange
	(14-1, Minamiichijonishi 5-chome,Chuo-ku, Sapporo)

- 1 -

Table of Contents

A. Company Information

I. Overview of Takeda

1. Key Consolidated Financial Data

		JPY (millions), unless otherwise indicated
		Six-month period		Six-month period		For the year ended
		ended September 30,		ended September 30,		March 31,
Term		2020		2021		2021
Revenue	1,590,785	1,794,423	3,197,812
<> period ended September 30>	788,935	844,819
Profit before tax	125,561	284,425	366,235
Net profit for the period	86,589	183,721	376,171
Net profit attributable to owners of the Company	86,548	183,648	376,005
<> period ended September 30>	4,037	45,964
Total comprehensive income for the period	64,443	270,288	697,416
Total equity	4,666,499	5,324,361	5,177,177
Total assets	12,414,747	12,560,273	12,912,293
Basic earnings per share (JPY)	55.45	117.08	240.72
<> period ended September 30>	2.58	29.24
Diluted earnings per share (JPY)	55.13	116.40	238.96
Ratio of equity attributable to owners of the Company to
total assets (%)	37.6	42.4	40.1
Net cash from (used in) operating activities	392,011	400,011	1,010,931
Net cash from (used in) investing activities	28,224	(103,349)	393,530
Net cash from (used in) financing activities	(418,210)	(658,405)	(1,088,354)
Cash and cash equivalents at the end of the period	630,868	607,881	966,222

(Note 1) All amounts shown are rounded to the nearest million JPY.

(Note 2) The key consolidated financial data for the six-month period ended September 30, 2020 and 2021 are based on the condensed interim consolidated financial statements prepared in accordance with IAS 34.

.

- 2 -

Table of Contents

2. Business Overview

There has been no significant change in our business for the six-month period ended September 30, 2021. Changes in number of our group companies were as follows:

During the three-month period ended June 30, 2021, Takeda added 1 subsidiary while deconsolidated 9 entities mainly due to the mergers and liquidations of subsidiaries acquired in the acquisition of Shire plc. In addition, Takeda added 1 associate accounted for using the equity method and excluded 1 entity from associates accounted for using the equity method.

During the three-month period ended September 30, 2021, Takeda deconsolidated 14 entities mainly due to the mergers and liquidations of subsidiaries acquired in the acquisition of Shire plc. In addition, Takeda added 1 associate accounted for using the equity method.

As a result, as of September 30, 2021, Takeda consisted of 240 entities comprised of 217 consolidated subsidiaries (including partnerships), 22 associates accounted for using the equity method, and Takeda Pharmaceutical Company Limited.

- 3 -